Unknown

Dataset Information

0

Fluoxetine as an anti-inflammatory therapy in SARS-CoV-2 infection.


ABSTRACT: Hyperinflammatory response caused by infections such as Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) increases organ failure, intensive care unit admission, and mortality. Cytokine storm in patients with Coronavirus Disease 2019 (COVID-19) drives this pattern of poor clinical outcomes and is dependent upon the activity of the transcription factor complex nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kappaB) and its downstream target gene interleukin 6 (IL6) which interacts with IL6 receptor (IL6R) and the IL6 signal transduction protein (IL6ST or gp130) to regulate intracellular inflammatory pathways. In this study, we compare transcriptomic signatures from a variety of drug-treated or genetically suppressed (i.e. knockdown) cell lines in order to identify a mechanism by which antidepressants such as fluoxetine demonstrate non-serotonergic, anti-inflammatory effects. Our results demonstrate a critical role for IL6ST and NF-kappaB Subunit 1 (NFKB1) in fluoxetine's ability to act as a potential therapy for hyperinflammatory states such as asthma, sepsis, and COVID-19.

SUBMITTER: Creeden JF 

PROVIDER: S-EPMC7904450 | biostudies-literature |

REPOSITORIES: biostudies-literature

Similar Datasets

| S-SCDT-10_1038-S44318-024-00061-0 | biostudies-other
| S-EPMC9657171 | biostudies-literature
| S-SCDT-10_15252-EMMM_202317376 | biostudies-other
| S-EPMC8272687 | biostudies-literature
| S-EPMC10987522 | biostudies-literature
| S-EPMC8118700 | biostudies-literature
| 12454 | ecrin-mdr-crc
| S-EPMC8372442 | biostudies-literature
2013-07-31 | E-GEOD-47960 | biostudies-arrayexpress
2013-07-31 | E-GEOD-47961 | biostudies-arrayexpress